Emerging Challenges In Primary Care: 2015
|
|
- Ferdinand Pierce
- 5 years ago
- Views:
Transcription
1 Care Se'ng Emerging Challenges In Primary Care: 2015 Chronic Hepatitis C: Update on Screening, Diagnosis, Management, and Promising New Treatments 1
2 Faculty Kalyan R. Bhamidimarri, MD, MPH Assistant Professor of Clinical Medicine University of Miami Miller School of Medicine Transplant Hepatology/ Medical Director of Small Bowel & MultiVisceral Transplant Miami Transplant Institute Miami, FL Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical Medicine Center for Liver Diseases Medical Director, Liver and GI Transplantation Miami Transplant Institute University of Miami School of Medicine Miami, FL Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD Leonard Miller Professor of Medicine Dr. Nasser Ibrahim Al-Rashid Chair Director, Schiff Center for Liver Diseases Director, Hepatology Research Laboratory University of Miami Miller School of Medicine Miami, FL Elliot Wortzel, MD, FACG, FACP Gastroenterology Weston, FL 2
3 Disclosures Kalyan R. Bhamidimarri, MD, MPH is a member of the scientific advisory board for Bristol Myers Squibb, Gilead Sciences, Janssen Therapeutics, AbbVie, Genentech. Dr. Bhamidimarri also receives research/grant support from Bristol Myers Squibb, Gilead Sciences, AbbVie, Vital Therapies Inc., Biotest Pharmaceuticals, Ocera Therapeutics Inc., Salix Pharmaceuticals, and Synageva. Christopher O'Brien, MD, AGAF, FRCMI conducts research for and receives research grants from Gilead, BMS, Abbott (Abbvie), and Janssen. Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD is a consultant for Gilead and Merck. He serves on the scientific advisory boards of Bristol Myers Squibb, Gilead, Janssen Pharma, and Acorda; and he serves on the data monitoring boards of Bristol Myers Squibb, Salix, Pfizer, and Arrowhead. Dr. Schiff receives grant/research support from Abbott, Bristol Myers Squibb, Gilead, Merck, Orasure Technologies, Roche Molecular, Janssen Pharma, Discovery Life Sciences, Beckman Coulter, Siemens, MedMira, and Conatus. Elliot Wortzel, MD, FACG, FACP has no relationships to disclose. 3
4 Learning Objectives After participating in the proposed educational activities, clinicians should be better able to: 1. Identify patients at risk for hepatitis C and explain the approach to screening and confirmation of the diagnosis in these patients 2. Discuss guidelines for the overall medical management of patients with hepatitis C 3. Discuss patient and viral factors that determine the appropriate drug treatment for patients with chronic HC infection 4. Distinguish patients who may be treated in the primary care setting from those who require specialty referral 4
5 PRE-TEST QUESTIONS 5
6 Pre-test Question 1 On a scale of 1 to 5, please rate how confident you would be treating a patient with Chronic Hepatitis C:! 1. Not at all confident " " 2. Slightly confident " " " 3. Moderately confident " "" 4. Pretty much confident " " 5. Very confident" " 6
7 Pre-test Question 2 Case A 55 year old Caucasian female presents with an upper GI bleed Endoscopy demonstrated esophageal varices that were banded to obliteration Routine labs revealed HCV Ab+ On further discussion she states that she: Drinks wine daily Has drastically reduced her work productivity due to debilitating fatigue 7
8 Pre-test ARS Question 2 How would you confirm the diagnosis of Hepatitis C in this patient? 1. HCV DNA 2. HCV RNA 3. HCV Ag 4. HCV Ab 8
9 Initial Testing Results HCV RNA 6.1 million IU/mL Genotype 1 AST; ALT 204 IU/L; 79 IU/L Platelets 99,000 cells/mm3 Ultrasound Nodular surface consistent with cirrhosis 9
10 Pre-test ARS Question 3 What factor below is not required to qualify the patient for drug treatment? 1. HCV genotype 1 2. Cirrhosis on ultrasound 3. Elevated AST and ALT 4. HCV RNA (+) 10
11 Pre-test Question 4 Pre-test ARS Question 4 You have decided to offer this patient treatment for HCV Type 1. Which treatment is not FDA approved for HCV Genotype 1? 1. Entecavir and ribavirin (Baraclude) 2. Ledipasvir and sofosbuvir (Harvoni) 3. Ombitasvir/paritaprevir/r + dasabuvir + ribavirin (Viekira Pak) 11
12 Pre-test ARS Question 5 All of the following strategies are required to monitor patients that have failed treatment for Hepatitis C except: 1. Monitor hepatic function panel and CBC every 6-12 months 2. Routine evaluation for cancer with CEA and AFP every 6 months 3. Liver US every 6 months in patients with advanced fibrosis and cirrhosis 4. Endoscopic surveillance for esophageal varices if cirrhotic 12
13 Outline Identify patients at risk for hepatitis C and explain the approach to screening and confirmation of the diagnosis in these patients Discuss patient and viral factors that determine the appropriate drug treatment for patients with chronic HC infection Recognize appropriate treatment options for patients with Hepatitis C Discuss guidelines for the overall medical management of patients with hepatitis C 13"
14 Worldwide Prevalence of HCV Infection ~180 Million With HCV Infection Prevalence of Infection >10% 2.5%-10% 1%-5% N/A 14
15 CDC Recommendations for HCV Screening Regardless of risk factors, one-time testing for HCV of adults born between Testing of persons of all ages at risk for HCV infection CDC also recommends for those identified with HCV infection Brief alcohol screening and intervention as clinically indicated Referral to appropriate care and treatment services for HCV infection and related conditions 15"
16 Deaths From HCV Have Surpassed Those From HIV Change in Mortality Rates From 1999 to 2007 Rate per 100,000 People HIV 15,106 12,734 Hepatitis C Hepatitis B 1, Year 16"
17 Liver Transplant Projection From 2013 to 2043 Potential Transplant Need: Treatment of all candidates and SVR of 90% will still require 22,000 transplants/year in , , , , ,747 Number of Persons 140, , ,000 80,000 60,000 40,000 20, ,296 91,310 49,013 18,193 25,573 27,175 26,207 24,258 21, No treatment 25% treated 50% treated 75% treated All treated Year in Model 17
18 HCV-Infected Persons in the US: Estimated Rates of Detection, Referral to Care and Cure CDC & USPSTF recommend 1-time testing of baby boomers (born ) X1000 persons % 32-38% 20-23% % 5-6% Infected Diagnosed Referred HCV RNA Treated Cure to care test 18"
19 Natural History of HCV Infection Leading to Liver Transplant Acute Infection (often asymptomatic) Progression to chronic infection (54%-86%) Cirrhosis ( 25% of chronic cases currently) ( 37% of chronic cases by 2020) Decompensated cirrhosis 11.7% of cirrhotics (5-year survival = 50%) Hepatocellular carcinoma (risk = 1%-5%/year) 18% in year after first decompensation Liver Transplant Death 19
20 Outline Identify patients at risk for hepatitis C and explain the approach to screening and confirmation of the diagnosis in these patients Discuss patient and viral factors that determine the appropriate drug treatment for patients with chronic HC infection Distinguish patients who may be treated in the primary care setting from those who require specialty referral Discuss guidelines for the overall medical management of patients with hepatitis C 20"
21 What Is an Elevated ALT Level? Reference ranges for ALT vary between 2 most widely used commercial laboratories Men: 4-60 IU/L; women: 6-40 IU/L Men: 0-55 IU/L; women: 0-40 IU/L Both AASLD and US treatment algorithms recommend lower ULN levels for ALT when making treatmentinitiation decisions 30 IU/L for men 19 IU/L for women 21"
22 Pretreatment Tests For Patients Who Will Start Treatment Assessment of hepatic fibrosis Assessment of potential drug:drug interactions HCV genotype and quantitative HCV viral load within 12 weeks of treatment start Other lab tests within 6 weeks of start of treatment CMP CBC INR 22"
23 Global Distribution and Prevalence of HCV Genotypes: US Focus on GT 1 23"
24 Baseline Viral Load Is Important If considering shorter duration (8 week) treatment for Genotype 1 patients, question(s) to ask: Has the patient been previously treated? If yes, baseline viral load does not matter If no and the patient is cirrhotic, baseline viral load does not matter If no and the patient is not cirrhotic, baseline viral load matters 24
25 GT 1 Treatment Naïve, Non-Cirrhotics: Baseline HCV RNA GuidesTreatment Duration LDV/SOF 8 Weeks (N=215) LDV/SOF 12 Weeks (N=216) SVR12 94% (202/215) 96% (208/216) Relapse Rates Overall <6 M IU/mL >6 M IU/mL 5% (11/215) 2% (2/123) 10% (9/92) 1% (3/216) 2% (2/131) 1% (1/85) 8 week LDV/SOF regimen should only be considered in GT 1, treatment-naïve, Non-cirrhotic patients Baseline viral load < 6 million IU/mL 25"
26 Assessment of Hepatic Fibrosis Is liver biopsy necessary for all HCVinfected patients before treatment? Alternatives to biopsy Transient elastography (FibroScan) Non-invasive assays (e.g., FibroTest, APRI, FIB-4) If a subset of patients should be biopsied, who are they? Important to identify patients with cirrhosis in order to define treatment duration 26
27 Cirrhosis Defined by Morphologic and Functional Changes of the Liver Normal Cirrhosis 27"
28 Indirect Markers of Fibrosis FibroTest/FibroSure Alpha-2 globulin Alpha-2 macroglobulin Gamma globulin Apoliprotein A1 GGT ActiTest Fibrotest +ALT Forns index APRI FIB-4 AST/ALT ratio AST/ALT with plts 28
29 Fibroscan 29
30 Fibroscan Propagation Speed Examples Low Speed 4 kpa High Speed 36 kpa 30"
31 Role of Liver Biopsy Needed less frequently Non-invasive tests improving Less essential for decisions regarding timing of treatment Worth considering if Non-invasive tests conflicting and need info to make treatment decision Suspect second disease: e.g. NASH Deferring treatment and concern for advanced disease 31"
32 Outline Identify patients at risk for hepatitis C and explain the approach to screening and confirmation of the diagnosis in these patients Discuss patient and viral factors that determine the appropriate drug treatment for patients with chronic HC infection Recognize appropriate treatment options for patients with Hepatitis C Discuss guidelines for the overall medical management of patients with hepatitis C 32"
33 Rising Cure Rates for Chronic HCV Telaprevir or Boceprevir + PegIFN/RBV 3 rd Gen 2 nd Gen DAAs DAAs IFN- Free IFN- Free Regimens Regimens Cure Rate* IFN IFN/RBV PegIFN/RBV Year 33"
34 When and in Whom to Initiate HCV Therapy: Highest Priority Advanced fibrosis (Metavir F3) or compensated cirrhosis (Metavir F4) Organ transplant; Rating Type 2 or 3 essential mixed cryoglobulinemia with endorgan manifestations (eg, vasculitis) Proteinuria, nephrotic syndrome, or membranoproliferative glomerulonephritis 34"
35 When and in Whom to Initiate HCV Therapy: High Priority Fibrosis (Metavir F2) HIV-1 coinfection HBV coinfection Other coexistent liver disease (eg, NASH) Debilitating fatigue; Rating Type 2 Diabetes mellitus (insulin resistant) Porphyria cutanea tarda;rating 35"
36 Common Minimal Prior Authorization Requirements HCV RNA within 3 months Genotype Staging of fibrosis Documented lack of abuse of alcohol or illicit drugs If simeprevir containing regimen, Q80K status May also require CBC, ALT, INR 36"
37 Each Drug Class Has Unique Features NS3/4A Protease Inhibitors! High efficacy" Low genetic barrier to resistance" Macrocyclic or linear" Simeprevir" Paritaprevir" NS5A Inhibitors!! NS5A has role in assembly of replication complex" Mechanism of inhibition under study" Ledipasvir" Ombitasvir" NS5B Polymerase Inhibitors! Nucleos(t)ide Analogue! Mimic natural substrates of the polymerase" Incorporated into RNA chain causing chain termination" Broad genotypic coverage" High genetic barrier to resistance" Sofosbuvir" Nonnucleos(t)ide! Bind to several different allosteric enzyme sites; results in conformational change" Resistance more frequent than nucs" Dasabuvir " " 37"
38 Recommended HCV Regimens for Treatment-Naïve Patients (Genotype 1) Duration of Therapy (weeks) Genotype 1a No Cirrhosis With Cirrhosis Genotype 1b No Cirrhosis With Cirrhosis Ledipasvir/sofosbuvir (90/400 mg qd) Sofosbuvir 400 mg + simeprevir 150 mg qd + RBV Ombitasvir/paritaprevir/r (25/150/100 mg qd) + dasabuvir 250 mg bid + RBV 12 (with RBV) 24 (with RBV) 12 (no RBV) 12 (with RBV) 38"
39 Recommended HCV Regimens for Treatment-Naïve Patients (Genotype 2, 3, 4, 5, 6) Genotype 2 Sofosbuvir + RBV for 12 weeks (16 weeks is recommended for cirrhotics) Genotype 3 Sofosbuvir + RBV for 24 weeks Genotype 4 Genotype 5 Ledipasvir/sofosbuvir (90/400 mg qd) for 12 weeks Sofosbuvir + RBV for 24 weeks Ombitasvir/paritaprevir/r (25/150/100 mg qd) + dasabuvir 250 mg bid + RBV for 12 weeks Sofosbuvir + PR for 12 weeks Genotype 6 Ledipasvir/sofosbuvir (90/400 mg qd) for 12 weeks 39"
40 On Treatment Monitoring CMP and CBC count Every 4 weeks More frequently for drug-related toxic effects (eg, CDC count for patients receiving RBV) Quantitative HCV viral load After 4 weeks of therapy At the end of treatment 12 weeks following completion of therapy 40"
41 Recommended HCV Regimens for Prior PegIFN + RBV Failure (Genotype 1) Duration of Therapy (weeks) Genotype 1a No Cirrhosis With Cirrhosis Genotype 1b No Cirrhosis With Cirrhosis Ledipasvir/sofosbuvir (90/400 mg qd) + RBV 12 (no RBV) 12 (with RBV) 24 (no RBV) 12 (no RBV) 12 (with RBV) 24 (no RBV) Sofosbuvir 400 mg + simeprevir 150 mg qd + RBV * Ombitasvir/paritaprevir/r (25/150/100 mg qd) + dasabuvir 250 mg bid + RBV 12 (with RBV) 24 (with RBV) 12 (no RBV) 12 (with RBV) 41"
42 Standard of Care for Treatment of Chronic HCV Infection (2015) Genotype! Regimen! Duration! Considerations! GT 2 " Sofosbuvir 400 mg QD + RBV 1000 or 1200 mg/day in 2 divided doses BID " 12 weeks" FDA approved" " GT 3 " " Sofosbuvir 400 mg QD + RBV 1000 or 1200 mg/day in 2 divided doses BID " 24 weeks" Data to support addition of PegIFN along with SOF + RBV for 12 weeks" GT 1 " " Sofosbuvir 400 mg QD weeks" FDA approved" Ledipasvir 90 mg QD (FDC) " [Paritaprevir/r + Ombitasvir] weeks " FDA approved" Dasabuvir BID ± RBV BID " 42"
43 Outline Identify patients at risk for hepatitis C and explain the approach to screening and confirmation of the diagnosis in these patients Distinguish patients who may be treated in the primary care setting from those who require specialty referral Recognize appropriate treatment options for patients with Hepatitis C Discuss guidelines for the overall medical management of patients with hepatitis C 43"
44 Post-Treatment Monitoring in Patients In Whom Treatment Failed To Achieve An SVR Disease progression assessment every 6-12 months with a hepatic function panel, CBC count and INR Surveillance for HCC with ultrasound testing every 6 months in those with advanced fibrosis / cirrhosis Endoscopic surveillance for esophageal varices if cirrhotic Evaluation for retreatment is recommended as alternative treatments become available 44"
45 Post-Treatment Follow-up in Patients Who Achieve An SVR F0-F2 Same as if they were never infected with HCV F3-F4 Surveillance for HCC with twice yearly ultrasound testing Baseline endoscopy to screen for varices if cirrhosis present (if found, treat and follow up as indicated) 45"
46 Prevalence of Cirrhosis The prevalence of cirrhosis, both worldwide and in the US, is difficult to know Cirrhosis is an outcome of a variety of causes; underlying cause is commonly used for surveillance purposes Compensated cirrhosis often goes undetected for prolonged periods of time Experts estimate that 5.5 million people in the United States have cirrhosis 46"
47 Progressive Increase in Incidence of HCV-Related Cirrhosis and HCC in US Annual Prevalence Rates Between 1996 and 2006 Among HCV-Infected Veterans 20% 5% C i r r h o s i s a n d D e c o m p e n s a t e d C i r r h o s i s 18% 16% 14% 12% 10% 8% 6% Decompensated Cirrhosis Cirrhosis HCC 4% 3% 2% 1% H e p a t o c e l l u l a r C a n c e r ( H C C ) 4% % 47"
48 Summary Active HCV infections with a detectable viral load are at increased risk of death due to hepatic and extrahepatic diseases Chronic HCV patients with active infection may benefit from antiviral treatment, once diagnosed, to reduce overall mortality Approval of newer, direct-acting, oral agents have high HCV cure rates, fewer adverse events, and negligible resistance compared with the first generation HCV protease inhibitors PegIFN & ribavirin based regimens are no longer recommended for treatment-naïve genotypes 1, 2, 3, 4, and 6s 48"
49 POST-TEST QUESTIONS 49
50 Pre-test Question 2 Case A 55 year old Caucasian female presents with an upper GI bleed Endoscopy demonstrated esophageal varices that were banded to obliteration Routine labs revealed HCV Ab+ On further discussion she states that she: Drinks wine daily Has drastically reduced her work productivity due to debilitating fatigue 50
51 Post-test ARS Question 1 How would you confirm the diagnosis of Hepatitis C in this patient? 1. HCV DNA 2. HCV RNA 3. HCV Ag 4. HCV Ab 51
52 Initial Testing Results HCV RNA 6.1 million IU/mL Genotype 1 AST; ALT 204 IU/L; 79 IU/L Platelets 99,000 cells/mm3 Ultrasound Nodular surface consistent with cirrhosis 52
53 Post-test ARS Question 2 What factor below is not required to qualify the patient for drug treatment? 1. HCV genotype 1 2. Cirrhosis on ultrasound 3. Elevated AST and ALT 4. HCV RNA (+) 53
54 Pre-test Question 4 Post-test ARS Question 3 You have decided to offer this patient treatment for HCV Type 1. Which treatment is not FDA approved for HCV Genotype 1? 1. Entecavir and ribavirin (Baraclude) 2. Ledipasvir and sofosbuvir (Harvoni) 3. Ombitasvir/paritaprevir/r + dasabuvir + ribavirin (Viekira Pak) 54
55 Post-test ARS Question 4 All of the following strategies are required to monitor patients that have failed treatment for Hepatitis C except: 1. Monitor hepatic function panel and CBC every 6-12 months 2. Routine evaluation for cancer with CEA and AFP every 6 months 3. Liver US every 6 months in patients with advanced fibrosis and cirrhosis 4. Endoscopic surveillance for esophageal varices if cirrhotic 55
56 Post-test Question 5 On a scale of 1 to 5, please rate how confident you would be treating a patient with Chronic Hepatitis C:! 1. Not at all confident " " 2. Slightly confident " " " 3. Moderately confident " "" 4. Pretty much confident " " 5. Very confident" " 56
57 Post-test Question 6 Which of the statements below describes your approach to treating Chronic Hepatitis C? 1. I do not treat patients with Chronic Hepatitis C, nor do I plan to this year. 2. I did not treat patients with Chronic Hepatitis C, but as a result of attending this course I m thinking of doing this now. 3. I do treat patients with Chronic Hepatitis C and this course helped me change my methods. 4. I do treat patients with Chronic Hepatitis C and this course confirmed that I don t need to change my methods 57
Emerging Challenges In Primary Care: 2015
Care Se'ng Emerging Challenges In Primary Care: 2015 Chronic Hepatitis C: Update on Screening, Diagnosis, Management, and Promising New 1 Faculty Kalyan R. Bhamidimarri, MD, MPH Assistant Professor of
More informationEmerging Challenges In Primary Care: Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor
More informationEmerging Challenges In Primary Care: 2015
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical
More informationEmerging Challenges In Primary Care: 2015
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2017 Bulletin #165 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: Only prescribers who have completed
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationLength of Authorization: 8-12 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &
More informationUpdates in the Treatment of Hepatitis C
Disclosures Updates in the Treatment of Hepatitis C Arslan Kahloon M.D Assistant Professor of Medicine University of Tennessee, Chattanooga I have no conflicts of interest or financial sponsorship to disclose
More informationHepatitis C Treatment in Oregon
The Hepatitis C Advisory Group, 12/21/2014 Hepatitis C Treatment in Oregon Introduction The rising health care burden of HCV infection in Oregon is occurring at this time of growing interest in containing
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: March 18, 2016 Harvoni Description Harvoni (ledipasvir
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Mavyret) Reference Number: CP.HNMC.39 Effective Date: 08.15.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationHepatitis C Update: A Growing Challenge With Evolving Management Solutions
Pts (%) Hepatitis C Update: A Growing Challenge With Evolving Management Solutions A Growing Challenge With Evolving Management Solutions Introduction Magda Houlberg, MD Chief Clinical Officer Howard Brown
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationChronic Hepatitis C: An Update on Screening, Evaluation, and Management
Chronic Hepatitis C: An Update on Screening, Evaluation, and Management Donald Gardenier, DNP, FNP-BC, FAANP, FAAN Assistant Professor and Clinical Program Director Icahn School of Medicine at Mount Sinai
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: December 2, 2016 Harvoni Description Harvoni (ledipasvir
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vosevi) Reference Number: CP.HNMC.41 Effective Date: 07.26.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationHepatitis C Virus Clinical Criteria Update September 18, For: New York State Medicaid
Hepatitis C Virus Clinical Criteria Update September 18, 2014 For: New York State Medicaid 1 Purpose Characterize the place in therapy for the agents utilized for management of chronic hepatitis C (CHC)
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationHepatitis C Direct-Acting Antivirals
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHepatitis C: the 2015 Perspective for the Family Medicine Practitioner
Hepatitis C: the 2015 Perspective for the Family Medicine Practitioner Annie Luetkemeyer, MD Division of HIV,ID & Global Medicine San Francisco General Hospital Disclosures I have received research grant
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationHepatitis C Prior Authorization Policy
Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationWHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT
WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationNew HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:
New HCV reimbursement criteria 01-2017 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ
More informationIt is the policy of health plans affiliated with Centene Corporation that Mavyret is medically necessary when the following criteria are met:
Clinical Policy: (Mavyret) Reference Number: CP.CPA.285 Effective Date: 08.15.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationBrief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV)
Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV) James Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital www.mghcme.org Disclosures Neither
More informationDisclosures. Outline Update on HCV management & treatment in Primary care. What role does the Family Practice Provider play in HCV care in 2014?
Disclosures 2014 Update on HCV management & treatment in Primary care Annie Luetkemeyer HIV Division San Francisco General Hospital I have received research grant support to UCSF related to HCV from the
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationTreating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World H. Nina Kim, MD MSc Associate Professor of Medicine University of Washington Division of Allergy & Infectious Diseases April 21, 2017
More informationChronic Hepatitis C Drug Class Monograph
Chronic Hepatitis C Drug Class Monograph Line of Business: Medi-Cal Effective Date: July 10, 2017 (Interim Guidelines; Final Review and Approval by the P&T Subcommittee Pending) This policy has been developed
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17
Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of this policy
More informationHepatitis C Update on New Treatments
Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationNew HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:
New HCV reimbursement criteria 01-2018 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationNew HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:
New HCV reimbursement criteria 01-2018 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ
More informationREQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments
Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber
More informationPARTNERSHIP HEALTHPLAN OF CALIFORNIA
Authorization for the Treatment of Hepatitis C 4665 Business Center Drive Fairfield, California 94534 October 1, 2017 Re: Authorization for the use of Mavyret/Zepatier/Epclusa/Harvoni/Viekira/Sovaldi/Daklinza/
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationHepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?
Hepatitis C Jennifer Acosta PA-C No disclosures 1. The USPSTF recommends Hepatitis C screening in which patient populations? a. All adults at least once b. Immigrants to the US and those over age 65 c.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Sovaldi) Reference Number: ERX.SPA.127 Effective Date: 10.01.16 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPMN.180
Clinical Policy: (Daklinza) Reference Number: ERX.SPMN.180 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationHepatitis C Virus Management
Hepatitis C Virus Management FDA-Approved Medications Hepatitis C is caused by a virus and results in liver inflammation, which can lead to advanced liver disease and/or liver cancer. An estimated 3 to
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 01/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPA.131 Effective Date:
Clinical Policy: (Daklinza) Reference Number: ERX.SPA.131 Effective Date: 10.01.16 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationTreatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy
Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy antonio.craxi@unipa.it Ad Board and grants: Abbvie, Achillion, BristolMyers Squibb,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Viekira XR, Viekira Pak) Reference Number: ERX.SPA.129 Effective Date: 10.01.16 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important
More informationAdvances in Chronic Hepatitis C Infection
Presenter Disclosure Information 9:45 1:45am Spotlight on Hepatitis C Infection SPEAKER Sammy Saab, MD, MPH, AGAF The following relationships exist related to this presentation: Sammy Saab, MD, MPH, AGAF:
More information